|
Biomarkers Research Initiatives in Mass Spectrometry Center (BRIMS)
Advancing Personalized Medicine
Technology innovations in mass spectrometry are driving the rapid development of clinical diagnostics, therapeutic drug monitoring and predisposition screening. It is likely that in the near future an individual's protein, genetic or metabolic profile will be used to determine predisposition to disease and to tailor medical care.
Advancing personalized medicine relies on the discovery and validation of protein and peptide biomarkers that signal disease states. Researchers have identified many putative biomarkers, but few have been independently validated. A key challenge is to break this bottleneck and bridge the gap between early-stage discovery and next-stage, routine quantitative application of biomarker assays in the clinical research setting.
Learn how we our workflow, collaborations and staff are advancing personalized medicine at BRIMS. |
Thermo Fisher Scientific BRIMS Center
The Biomarkers Research Initiatives in Mass Spectrometry Center (BRIMS) provides applications assistance in biomarker discovery and verification.
Learn how we're advancing mass spectrometry (MS)-based workflows to bridge the gap between early-stage discovery and next-stage, routine verification and validation of biomarkers.
Follow BRIMS on Facebook
|
|
The BRIMS Center collaborates with leading clinical researchers and technology providers. These collaborations speed validation of biomarkers and workflows, and demonstrate the reproducibility of SRM-based assays and usefulness of BRIMS Center-developed technologies. They also provide a valuable source of clinical expertise, samples, and input for product and workflow development, and keep our staff at the forefront of clinical research needs. Learn more on about our collaborations on Facebook.
|
BRIMS Center Collaborations
|
| Dr. Randall Nelson, Arizona State University (ASU) and Dr. Ravinder Singh, MAYO Clinic |
Dr. Eleftherios Diamandis, Mt. Sinai and Toronto's University Health Network (UHN) |
| Dr. Kypros Nicolaides, Fetal Medicine Foundation, London, UK |
NextGen Sciences |
| Dr. Emanuel Petricoin and Dr. Lance Liotta, George Mason University (GMU) |
Proteome Sciences |
| Dr. Sarah Fortune, Harvard School of Public Health |
Dr. Toshihide Nashimura, Tokyo Medical University Hospital and Dr. Gyorgy Marko-Varga, Tokyo Medical University Hospital and Lund University, Sweden |
| Intrinsic Bioprobes (IBI) |
Dr. Kevin Rosenblatt, University of Texas Medical Branch (UTMB), Dr. Makoto-Kuro-O, University of Texas Southwestern Medical Center (UTSW), and Dr. Orson Moe, UTSW |
| Dr. Daniel Chan, Johns Hopkins University |
|
|
Our family of global service brands provide a complete portfolio of laboratory equipment, chemicals, supplies and services for research, safety, healthcare and science education.
Find your Fisher location:
US | Canada | Asia Pacific | Europe | Latin America |
